Skip to main content

Incidence of Autoimmune Disease Increased After Surgical Remission of Cushing

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 20, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, Feb. 20, 2024 -- Patients achieving surgical remission of Cushing disease (CD) have a higher incidence of autoimmune disease compared with those with nonfunctioning pituitary adenomas (NFPAs), according to a study published online Feb. 20 in the Annals of Internal Medicine.

Dennis Delasi Nyanyo, from Massachusetts General Hospital in Boston, and colleagues conducted a retrospective matched cohort analysis to examine the incidence of autoimmune disease in patients with CD after surgical remission and those with NFPAs.

The researchers found that at three years after surgery, the cumulative incidence of new-onset autoimmune disease was higher in patients with CD than NFPAs (10.4 versus 1.6 percent; hazard ratio, 7.80). A higher prevalence of postoperative adrenal insufficiency (93.8 versus 16.5 percent) and lower postoperative nadir serum cortisol levels (63.8 versus 282.3 nmol/L) were seen for patients with CD versus those with NFPAs. CD patients who developed autoimmune disease had a lower preoperative 24-hour urine free cortisol ratio (2.7 versus 6.3) and a higher prevalence of a family history of autoimmune disease (41.2 versus 20.9 percent) compared with those without autoimmune disease.

"To our knowledge, this is the first matched cohort study to confirm an association between CD remission and development of autoimmune disease," the authors write. "The proinflammatory state after CD remission serves as a model for increased immunoreactivity after reversal of hypercortisolemia in acute stress, illness, or withdrawal of glucocorticoids."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

No Association Found for Autoimmune Disease, Monoclonal Gammopathy

MONDAY, May 20, 2024 -- In a systematically screened population, there is no association between autoimmune disease and monoclonal gammopathy of undetermined significance (MGUS)...

CAR T-Cell Therapy Feasible, Safe for Autoimmune Diseases

WEDNESDAY, Feb. 21, 2024 -- CD19 chimeric antigen receptor (CAR) T-cell therapy seems feasible, safe, and efficacious for patients with different autoimmune diseases, according to...

Link Between Inflammatory Disease, Adverse Pregnancy Outcomes Varies

MONDAY, Feb. 12, 2024 -- The association between immune-mediated inflammatory diseases (IMIDs) and adverse pregnancy outcomes varies with the nature of IMID and the presence of...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.